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Abstract
Background
Despite evidence supporting an involvement of mitochondrial dysfunction in the pathogene-
sis of some neurodegenerative disorders, there are inconsistent findings concerning mito-
chondrial haplogroups and their association to neurodegenerative disorders, including
idiopathic Parkinson’s disease (PD).
Methods
To test this hypothesis for the Greek-Cypriot population, a cohort of 230 PD patients and
457 healthy matched controls were recruited. Mitochondrial haplogroup distributions for
cases and controls were determined. Association tests were carried out between mitochon-
drial haplogroups and PD.
Results
Mitochondrial haplogroup U was associated with a reduced PD risk in the Cypriot popula-
tion. After pooling mitochondrial haplogroups together into haplogroup clusters and super-
clusters, association tests demonstrated a significantly protective effect of mitochondrial
haplogroup cluster N (xR) and supercluster LMN for PD risk only in females. In addition, for
female PD cases belonging to UKJT and R (xH, xUKJT) haplogroup, the odds of having a
PLOS ONE | https://doi.org/10.1371/journal.pone.0183444 September 6, 2017 1 / 11
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Georgiou A, Demetriou CA, Heraclides A,
Christou YP, Leonidou E, Loukaides P, et al. (2017)
Mitochondrial superclusters influence age of onset
of Parkinson’s disease in a gender specific manner
in the Cypriot population: A case-control study.
PLoS ONE 12(9): e0183444. https://doi.org/
10.1371/journal.pone.0183444
Editor: Cristina Cereda, Centre of Genomic & Post
Genomics, ITALY
Received: February 21, 2017
Accepted: August 6, 2017
Published: September 6, 2017
Copyright: © 2017 Georgiou et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The study consumables and direct
expenses were funded by the Cyprus Institute of
Neurology and Genetics and the Cyprus School of
Molecular Medicine. Andrea Georgiou received
funding from A. G. Leventis Foundation. All other
authors received no specific funding for this work.
later age of onset of PD were 13 and 15 times respectively higher than the odds for female
cases with an H haplogroup.
Conclusion
Statistically significant associations regarding PD risk and PD age of onset were mostly
detected for females thus suggesting that gender is a risk modifier between mitochondrial
haplogroups and PD status / PD age of onset. The biological mechanisms behind this gen-
der specificity remain to be determined.
Introduction
Parkinson’s disease (PD) affects a substantial proportion of the elderly European population,
including the Cypriot population. PD affects about 1% of the population over 60 years old in
industrialized countries and this is expected to double in the next decades [1]. The prevalence
and incidence rates of PD increase with age, having a steeper rise in individuals over 60 years
old [2]. Sporadic PD accounts for at least 90% of the cases.
Moreover PD is a multifactorial disease caused by both genetic and environmental risk fac-
tors [3]. PD is characterized by selective loss of dopamine secreting neurons [1] and accumula-
tion of Lewy bodies [4] in the brain and spinal cord. Midbrain dopaminergic neurons have a
high rate of metabolic activity and are therefore dependent on the energy (ATP) released by
oxidative phosphorylation in mitochondria. [5, 6] Consequently, mitochondrial dysfunction
caused by genetic variants in both mitochondrial and nuclear DNA, can adversely affect neu-
ronal function and lead to neurodegenerative diseases, such as Alzheimer’s disease (AD) and
PD. Therefore PD pathogenesis has been strongly associated with both nuclear and mitochon-
drial genetic variants [7, 8].
Any population can be subdivided into phylogenetic clusters called mitochondrial hap-
logroups, which are characterized by specific mitochondrial polymorphisms that are inherited
maternally through generations. The most common Western Eurasian mitochondrial hap-
logroups are H, I, J, K, T, U, V, W and X, which arose from the African super-haplogroup L3
[9]. Numerous studies have examined whether mitochondrial haplogroups are associated with
the pathogenesis and risk of developing PD. Some mitochondrial haplogroups such as K and J
have been found to be associated with a reduced risk of PD independently [10, 11] or after
pooling them into the super-haplogroup UKJT in specific populations [12, 13]. However,
there are some studies that did not find any association between mitochondrial haplogroups
and PD. [14–16] Inconsistent results probably arise from the fact that participants in each
study come from different populations with different mitochondrial genetic lineages and dif-
ferent frequencies of the aforementioned haplogroups. In addition, statistical variations in the
sample size and approach used, such as choice of statistical tests, confounding factors, and cor-
rections for multiple testing, may also explain a large proportion of the variation in the associa-
tions observed [16].
The Cypriot population results from the genetic admixture of several populations mainly
from Eastern and Southern Europe and Western Asia (http://www.admixturemap.
paintmychromosomes.com/) [17]. Therefore, due to high genetic admixture Cypriots have
moderate genetic heterogeneity which is translated into a high diversity in mtDNA (mitochon-
drial DNA) gene pool. Interestingly, mitochondrial haplogroup K, which has been previously
linked to lower PD risk, is particularly common in the Cypriot population, in frequencies
Mitochondrial DNA haplogroups and Parkinson’s disease in the Cypriot population
PLOS ONE | https://doi.org/10.1371/journal.pone.0183444 September 6, 2017 2 / 11
Competing interests: The authors have declared
that no competing interests exist.
much higher than other surrounding populations [18]. Herein we aim to investigate the pres-
ence of associations between mtDNA haplogroups and the risk for PD in the Cypriot popula-
tion. A secondary aim, comprising a novel investigation, adding to the existing literature, is
testing for any association between mitochondrial DNA haplogroups and PD age of onset and
PD symptoms in the Cypriot population.
Materials and methods
Sample recruitment
A cohort of 230 PD patients was recruited from the Cyprus Institute of Neurology and Genet-
ics (CING) and other medical centers across Cyprus (mean age 66.5 ± 10.5 years, mean age-of-
onset 60.4 ± 11.4 years, 54.5% males and 45.5% females). Selection criterion for patient’s inclu-
sion in the study was clinical diagnosis of PD by a board certified neurologist, followed by a
clinical evaluation during the study, using the UPDRS rating scale by a board certified CING
neurologist. Patients that had clinical signs suggestive of Parkinsonian syndromes were
excluded. All patients were Greek-Cypriots.
Four hundred and fifty seven ethnically-matched controls were recruited using random
cluster sampling from the general population. Cluster sampling included mailing letters of
invitation to residences in randomly selected postal codes as well as visiting randomly selected
medical/community centers across Cyprus. Individuals that did not suffer from any neurode-
generative disorder or cognitive impairment were invited to participate. Controls were45
years old (mean age 65 ± 10.7 years, 50% males and 50% female).
The study was approved by the Cyprus National Bioethics Committee and all study partici-
pants, or their legal proxy, signed an informed consent form after detailed information regard-
ing study participation was given.
Participants initially underwent an interview through an anonymized questionnaire that
collected data regarding demographics, environmental exposures, medical history, lifestyle
and other relevant characteristics such as diet, smoking, alcohol and coffee consumption. Sub-
sequently, a peripheral blood sample or saliva was collected from all participants.
Genotyping, determination and classification of mtDNA haplogroups
Total genomic DNA was isolated from peripheral-blood lymphocytes or saliva samples using
the QIAamp DNA Blood Mini kit (Qiagen) following the manufacturer’s instructions. Poly-
merase chain reaction was used to amplify the entire mitochondrial DNA (mtDNA) Hypervar-
iable Region 1 (HVR 1). Following PCR purification, direct sequencing was carried out using
the BigDye Terminator cycle sequencing kit v 3.1 (Thermo Fisher Scientific). The produced
sequence was aligned and compared against the revised Cambridge Reference Sequence
(rCRS, Genbank: NC_012920) using SeqScape software (Thermo Fisher Scientific). The collec-
tive HVR 1 polymorphism information for all study participants was entered into an electronic
database. Conversion of the annotated mitochondrial DNA HVR 1 variants into mitochon-
drial DNA haplogroups was performed using the 2.0 beta version of the web-based prediction
tool HaploGrep (http://haplogrep.uibk.ac.at) [19] The predicted haplogroups were confirmed
by testing the corresponding mtDNA coding region branch-defining SNPs by direct sequenc-
ing for all the samples (Table 1). The major mitochondrial haplogroups presented in Table 2
were further clustered into haplogroup-clusters based on common ancestors that they share
and consequently common coding-region defining SNPs (Phylotree Build 17: www.phylotree.
org) (Table 1) [20]. Haplogroup-clusters were then joined into superclusters based on previous
studies, in order to compare our findings with other published studies that have used the same
approach [12, 15]. As a result, the frequency of the independent variable was increased and
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accordingly the study power. The clusters created were L (xM, xN), M, N (including N, W, X
and I) (xR), R (R, R0), HV (HV, V), JT and U (including K) and the superclusters were LMN
(including L, M, N, W, X and I), UKJT (including U, K, J and T) and R (including R, R0, HV
and V) (xH, xUKJT).
Table 1. MtDNA coding region branch-defining SNPs* for each haplogroup as used in the current study among a sample of Cypriot PD cases and
controls.
SNPs genotyped
Haplogroup 1243
T/C
3594
C/T
3594
C/T
4580
G/A
6371
C/T
7028
T/C
10034
T/C
10238
T/C
10400
C/T
11467
A/G
10550
A/G
12612
A/G
12705
T/C
13368
G/A
14766
T/C
16126
T/C
W C C C G C T T T C A A A T G T T
L3’4 T C C G C T T T C A A A T G T T
L 0/1/2 T T T G C T T T C A A A T G T T
V T C C A C T T T C A A A C G C T
X T C C G T T T T C A A A C G T T
H T C C G C C T T C G A A C G C T
I T C C G C T C C C A A A C G T T
N1 T C C G C T T C C A A A C G T T
M T C C G C T T T T A A A T G T T
U T C C G C T T T C G A A C G T T
K T C C G C T T T C G G A C G T T
J T C C G C T T T C A A G C G T C
R* T C C G C T T T C A A A C G T T
T T C C G C T T T C A A A C A T C
HV T C C G C T T T C A A A C G C T
JT T C C G C T T T C A A A C G T C
* Numbering according to GenBank number NC_012920
https://doi.org/10.1371/journal.pone.0183444.t001
Table 2. Distribution of mtDNA haplogroups between Cypriot PD patients and controls and Odds Ratios (95% Confidence Intervals) showing their
association with PD.
Haplogroup Cases Controls Adjusted Model Association*
N (%) N (%) OR p-value**
H 82 (35.7) 132 (28.9) 1 reference
I 3 (1.3) 12 (2.6) 0.47 (0.13–2.75) 0.62
U 21 (9.1) 70 (15.32) 0.49 (0.28–0.92) 0.02
K 22 (9.6) 52 (11.38) 0.74 (0.41–1.34) 0.32
J 17 (7.4) 26 (5.6) 1.22 (0.61–2.43) 0.56
T 27 (11.8) 51 (11.2) 0.93 (0.53–1.61) 0.79
W 5 (2.2) 15 (3.3) 0.61 (0.20–1.63) 0.36
HV 19 (8.3) 26 (5.7) 1.30 (0.61–2.47) 0.45
X 12 (5.2) 26 (5.7) 0.86 (0.40–1.86) 0.70
N (xWXI, xR) 5 (2.2) 16 (3.5) 0.55 (0.19–1.55) 0.26
M 4 (1.7) 9 (2.0) 0.91 (0.27–3.10) 0.88
L (xM, xN) 3 (1.3) 6 (1.3) 0.92 (0.22–3.84) 0.91
R (R*, R0) 10 (4.4) 16 (3.5) 1.12 (0.47–2.65) 0.80
*Logistic regression model adjusted for age, gender and maternal place of origin (PD:outcome, haplogroups: exposure)
** P-value nominal significance threshold = 0.05, Bonferroni adjusted significance threshold = 0.004
https://doi.org/10.1371/journal.pone.0183444.t002
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Statistical analysis
Statistical analysis was performed using STATA V12 SE (StataCorp) statistical software pack-
age. Chi-square test with Yates correction was used to assess any significant difference in the
overall mitochondrial haplogroup frequency distribution between PD cases and controls. The
association between specific mitochondrial haplogroups and PD was further evaluated using
binary logistic regression, in order to also adjust for potential confounders such as age, sex and
place of origin. Haplogroups were tested individually and as superclusters that share common
ancestors. The most common haplogroup (H) was used as the reference and this choice has
the advantage that it is more homogeneous than a pooling of different haplogroups [21].
In the Logistic regression models, mitochondrial haplogroup variables were treated as the
main exposure and PD status as the binary outcome. In addition, the same analysis was
repeated with age of PD onset as the main outcome. Age of onset did not pass regression diag-
nostic tests for linear modelling assumptions, even after transformation attempts. Therefore
the age of onset variable was separated into two categories, using the median age of onset (62
years) as a cut-off: earlier age of onset of PD (EOPD) with age of onset <62 years (reference
category) and later age of onset of PD (LOPD) with age of onset 62 years (event category).
Additionally logistic regression was used to evaluate the association between mitochondrial
haplogroup frequencies and PD symptoms such as tremor and bradykinesia-dyskinesia.
Nominal statistical significance was established at p-value < 0.05 and Bonferroni correction
was used to correct for multiple tests, dividing 0.05 by the number of mtDNA haplogroups,
clusters or super-clusters that represent independent branches of the mtDNA phylogeny [16,
22].
Results
Table 2 summarizes the distribution of mitochondrial haplogroups for both PD cases and con-
trols. All nine major Western Eurasian haplogroups are present, as well as the more basal
macro-haplogroups L, M, N and R. A major finding regarding haplogroup distribution in the
Cypriot population is that mitochondrial haplogroup H is underrepresented whereas hap-
logroup K is overrepresented (Table 2), compared to other European countries, [10, 12, 14,
15].
Chi-square test did not reveal any significant differences in the overall haplogroup distribu-
tion between cases and controls (χ2 = 11.94, p-value = 0.45). Mitochondrial haplogroup U
showed a nominally significant lower risk for PD (OR = 0.51, p-value = 0.03, 95%CI = 0.28–
0.92). However, the association did not survive Bonferroni correction (Table 2).
The three superclusters and six clusters were tested for any association between cases and
controls against haplogroup H, after adjusting for age, gender and maternal place of origin
(Table 3). The association test for haplogroup clusters revealed a nominally significant protec-
tive association for U cluster and PD, when compared to haplogroup cluster HV. After stratifi-
cation by gender U cluster did not preserve association in any of the two genders, while NWXI
cluster displayed a significantly protective association for females, which survived Bonferroni
correction (OR = 0.26, p-value = 0.006, 95% CI = 0.10–0.68). No significant difference between
the supercluster distributions between cases and controls was observed. However, after stratifi-
cation by gender, the supercluster LMN revealed a statistically significant protective effect for
PD in comparison to the reference haplogroup H only for the female gender (OR = 0.34, p-
value = 0.01, 95% CI = 0.15–0.77). This association was still statistically significant after cor-
recting for multiple testing.
Age of onset was converted into a binary variable consisting of 103 EOPD and 118 LOPD
cases. Superclusters were then tested for any association with the age of onset. Patients that
Mitochondrial DNA haplogroups and Parkinson’s disease in the Cypriot population
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belonged to the supercluster UKJT had a significant association with LOPD compared to the
reference haplogroup H (OR = 4.09, p-value = 0.005, 95% CI = 1.5–10.9) and after stratifica-
tion by gender, this association appeared even stronger in females (Table 4). More specifically
female cases belonging to UKJT mitochondrial supercluster had 13 times higher probability of
having LOPD compared to those with an H haplogroup and the association survived Bonfer-
roni correction. Additionally there was a statistically significant association between the R
supercluster and a later age of onset only for female patients (see Table 4). These results suggest
that gender is an effect modifier for PD and this was further supported for UKJT when an
interaction term was entered into the model with age of onset as the outcome, resulting in a
statistically significant interaction (pinteraction for UKJT = 0.02). For R (xH, xUKJT) the interac-
tion term approached but did not reach statistical significance (pinteraction for R (xH, xUKJT) =
0.056).
PD symptoms such as tremor and bradykinesia did not show any statistically significant
association with any mitochondrial haplogroup or supercluster (S1 and S2 Tables).
Table 3. Odds Ratios (95% Confidence Intervals) showing associations between mitochondrial haplogroup clusters and superclusters and PD.
All participants Males Females
Haplogroup-clusters OR (95%CI)* p-value** OR (95%CI)1 p-value** OR (95%CI)1 p-value**
H 1 reference 1 reference 1 reference
HV (HV, V) 1.29 (0.64–2.60) 0.48 2.02 (0.68–6.03) 0.21 0.94 (0.36–2.46) 0.90
U (including K) 0.61 (0.38–0.98) 0.03 0.68 (0.36–1.30) 0.24 0.58 (0.29–1.15) 0.12
JT 1.03 (0.64–1.65) 0.91 1.32 (0.68–2.57) 0.41 0.85 (0.43–1.68) 0.63
R (R*, R0) 1.01 (0.42–2.37) 0.98 0.77 (0.22–2.66) 0.68 1.78 (0.49–6.42) 0.38
N (xR) 0.65 (0.38–1.13) 0.10 1.23 (0.60–2.49) 0.57 0.26 (0.10–0.68) 0.006
M 0.92 (0.27–3.13) 0.90 0.76 (0.14–4.14) 0.75 1.08 (0.18–6.38) 0.94
L (xM, xN) 0.92 (0.27–3.13) 0.90 0.92 (0.08–10.74) 0.95 0.70 (0.12–4.18) 0.70
Superclusters OR (95%CI)* p-value*** OR (95%CI)1 p-value*** OR (95%CI)1 p-value***
H 1 reference 1 reference 1 reference
UKJT 0.78 (0.53–1.15) 0.21 0.91 (0.53–1.56) 0.73 0.71 (0.40–1.25) 0.23
R (xH, xUKJT) 1.19 (0.67–2.12) 0.55 1.11 (0.53–2.85) 0.80 1.32 (0.58–3.0) 0.58
LMN 0.69 (0.41–1.13) 0.14 1.11 (0.58–2.23) 0.75 0.34 (0.15–0.77) 0.01
*Logistic Regression Model for both genders adjusted for age, gender and maternal place of origin
1 Logistic Regression Model for males and females separately adjusted for age and maternal place of origin
** P-value nominal significance threshold = 0.05, Bonferroni adjusted significance threshold = 0.007
*** P-value nominal significance threshold = 0.05, Bonferroni adjusted significance threshold = 0.017
https://doi.org/10.1371/journal.pone.0183444.t003
Table 4. Odds Ratios (95% Confidence Intervals) showing associations between Cypriot mitochondrial haplogroup superclusters and age of PD
onset (EOPD versus LOPD).
All participants Males Females
mtDNA Superclusters OR (95%CI)* p-value** OR (95%CI)* p-value** OR (95%CI)* p-value**
H 1 reference 1 reference 1 reference
UKJT 4.07 (1.5–10.9) 0.005 1.42 (0.3–6.1) 0.64 13.55 (2.8–64.7) 0.001
LMN 0.69 (0.2–2.6) 0.58 0.29 (0.05–1.8) 0.19 2.49 (0.2–25.1) 0.44
R (xH, xUKJT) 3.42 (0.96–12.2) 0.06 1.14 (0.2–6.6) 0.88 15.84 (1.7–144) 0.014
* Logistic Regression Model adjusted for age and maternal place of origin
** P-value Nominal significance threshold = 0.05, Bonferroni adjusted significance threshold = 0.017
https://doi.org/10.1371/journal.pone.0183444.t004
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Discussion
The hypothesis whether mitochondrial DNA polymorphisms are associated with PD patho-
genesis is controversial. In this study we found an association between the mitochondrial hap-
logroup U (xK) and PD, with individuals belonging to the specific haplogroup having ~50%
lower likelihood of having PD in our sample. None of the previous studies have reported a sta-
tistically significant association between the U haplogroup and PD. Additionally, this associa-
tion did not survive Bonferroni correction, and thus the possibility of it being a false positive
result cannot be eliminated.
However, there are numerous other studies that have found evidence for association
between PD and haplogroups U, J and K. Van der Walt et al [2003] have reported a lower fre-
quency of haplogroups J and K in PD cases compared to controls [21]. A larger study 2 years
later by Ghezzi et al. [2005] has found that haplogroup K, but not J was significantly underrep-
resented in cases than controls, especially in males [10]. Furthermore, Gaweda et al. [2008]
have reported a protective association between haplogroup J and PD only in males [11]. Yet,
this finding is inconsistent with two other studies, concerning other European populations
that did not detect any association between mitochondrial haplogroups and PD [14–16].
Inconsistent results in the reported studies probably arise from the fact that participants in
each study come from different populations with different genetic lineages and different popu-
lation frequencies of the aforementioned haplogroups, as well as their subclades. For example,
subclades of mitochondrial Haplogroup U among Cypriots are not the same as U subclades
found in continental Europe [18, 23, 24].
In addition, the inconsistent and contradictory results on associations between mitochon-
drial haplogroups and PD may also be explained by the fact that most of the available studies
have a small sample size, lending themselves to both false positive and false negative findings
(i.e. type I and II errors). Furthermore, statistical variations in the approach used, such as con-
founding factors included, and corrections for multiple testing, may also explain a large pro-
portion of the variation in the associations observed [16].
Even though some of the aforementioned studies did not adjust for any confounders, the
majority of studies has adjusted their analyses, for age and gender, but has not performed pop-
ulation stratification. Adjusting for confounders is very important in terms of false positive
results as demonstrated in the present study where adjustment for confounders explained
away mitochondrial cluster N (xR) and supercluster LMN’s significant protective association
with PD (S3 Table).
A meta-analysis study aimed to resolve at least part of the inconsistency of studies by com-
bining the data from multiple association studies concerning mitochondrial haplogroups and
a variety of diseases such as PD, AD, breast cancer and Type 2 Diabetes. The results of this
study showed that individuals with the haplogroup K had a significantly decreased risk for PD
onset. Also haplogroups J and T are associated with protection against PD, while haplogroup
H is associated with an increased susceptibility to age-related diseases. Haplogroups H, K and J
are associated with multiple diseases, which suggest that the genetic variations that define
those haplogroups could have a pleiotropic impact on human diseases. The exact biological
mechanisms involved in this pleiotropic impact of mtDNA variants remains unclear. Further
functional studies on mitochondrial pathways such as oxidative phosphorylation and apopto-
sis could shed light on this [25].
In order to increase the frequency of the independent variable and consequently increase
the study power, mitochondrial haplogroups were combined into clusters and super-clusters
of haplogroups that share common ancestors. Combination of haplogroups into haplogroup
clusters and super-clusters revealed once more an association only for cluster U (including K)
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and PD. After stratification by gender, NWXI haplogroup cluster and LMN super-cluster
showed evidence for association with PD only for females, both of which survived Bonferroni
correction. This suggests that NWXI mitochondrial cluster drives the association between
LMN supercluster and PD among the female cases.
Finally, UKJT super-cluster showed a statistically significant association with a later age of
onset of PD when compared to the common haplogroup H. This association of the UKJT
supercluster and PD was even stronger in female cases and the association survived multiple
testing correction. Female PD cases who belong to cluster UKJT have 13.5-fold higher likeli-
hood of being diagnosed at a later age (>62 years) compared to those belonging to haplogroup
H. Additionally R (xH, xUKJT) haplogroup showed evidence for a protective association in
respect to the age of onset of PD, only among females. This suggests that gender is an effect
modifier between mitochondrial haplogroups and the age of onset of PD and could explain at
least in part, the fact that females have on average a later age of onset of PD than males [26].
Therefore there might be specific mitochondrial polymorphisms which are shared by certain
mtDNA haplogroups that affect mitochondrial function to a much greater extent in females
than in males. This possibility might be explained by the fact that estrogen receptors (ERs),
activated by estrogen female hormones, bind to mitochondrial estrogen responsive elements
(mtEREs) and this binding of ERs to the mtEREs increases the expression of mitochondrial
genes that are associated with the electron transport chain [27–29]. Certainly this is only a
hypothesis, which should be investigated further. However, there are a number of other publi-
cations reporting female genetic distribution bias and maternal inheritance bias on mtDNA in
PD patients. For example, in Chu et al. (2015), a susceptibility locus combined with haplotype
has been shown to influence PD risk, only in females [30].
This study is the first investigation of mtDNA haplogroups and PD risk in the Cypriot pop-
ulation and, to the best of our knowledge, the first investigation of the association between
mtDNA haplogroups and PD age of onset and PD symptoms. This is a nationwide investiga-
tion, recruiting cases and controls from all districts of Cyprus, minimizing thus the risk of bias
due to founder effect and maximizing the findings’ external validity. Furthermore, the mtDNA
haplogroup designations were not based merely on predictions from publicly available soft-
ware, but they were confirmed through further SNP analyses. Lastly, the study serves to high-
light the most important challenges regarding existing studies in the field of mtDNA
haplogroups and PD risk, especially the importance of correcting for confounders and multi-
ple testing, as well as gender stratification.
The current study is not without limitations, its small sample size leading to low study
power being perhaps its greatest restriction. This is particularly relevant to the age of onset
regression analysis. A larger sample size would be more preferable, in order to detect even
small associations between certain haplogroups and PD, if they existed [31]. However, given
the fact that Cyprus is a small country and the fact that PD is not a common disease, although
it affects a substantial proportion of the elderly population, a larger sample size comprising of
more cases, was almost impossible to recruit. The bradykinesia and dyskinesia of PD patients
also contributed to the limited sample size since it often translated into a reduced willingness
to participate in the study.
In conclusion, in this novel investigation, mitochondrial haplogroup U was associated with
a reduced PD likelihood in the Cypriot population. Furthermore, there was a significant pro-
tective association between haplogroup cluster NWXI and PD only in females. Most impor-
tantly, a statistically significant protective effect of supercluster UKJT and R (xH, xUKJT) with
respect to a later age of onset of PD when compared with haplogroup H was demonstrated for
the first time, in female PD patients. The biological mechanisms behind this novel finding
remain to be determined in future investigations.
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